The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD

The European Respiratory Journal
D SinghKenneth Newman

Abstract

We investigated the short-term bronchodilator effects of RPL554 (an inhaled dual phosphodiesterase 3 and 4 inhibitor) combined with other bronchodilators in chronic obstructive pulmonary disease patients with reversibility (>150 mL to short-acting bronchodilators).Study 1 was a six-way, placebo-controlled crossover study (n=36) with single doses of RPL554 (6 mg), salbutamol (200 µg), ipratropium (40 µg), RPL554 (6 mg)+salbutamol (200 µg), RPL554 (6 mg)+ipratropium (40 µg) or placebo. Study 2 was a three-way crossover study (n=30) of tiotropium (18 µg) combined with RPL554 (1.5 or 6 mg) or placebo for 3 days. Forced expiratory volume in 1 s (FEV1), lung volumes and specific airway conductance (sGaw) were measured.In study 1, peak FEV1 change compared with placebo was similar with RPL554, ipratropium and salbutamol (mean 223, 199 and 187 mL, respectively). The peak FEV1 was higher for RPL554+ipratropium versus ipratropium (mean difference 94 mL; p<0.0001) and RPL554+salbutamol versus salbutamol (mean difference 108 mL; p<0.0001). In study 2 (day 3), both RPL554 doses caused greater peak FEV1 effects than placebo. The average FEV1(0-12 h) increase was greater with RPL554 6 mg only versus placebo (mean difference 65 mL; p=0.0009). ...Continue Reading

References

May 13, 1998·British Journal of Clinical Pharmacology·P G BardinS T Holgate
Sep 3, 1999·American Journal of Respiratory and Critical Care Medicine·S MyouT Matsuda
Aug 2, 2005·The European Respiratory Journal·M R MillerUNKNOWN ATS/ERS Task Force
Jun 11, 2009·British Journal of Pharmacology·Katharine H Banner, Neil J Press
Jun 23, 2011·Handbook of Experimental Pharmacology·C P Page, D Spina
Jun 15, 2013·The Journal of Pharmacology and Experimental Therapeutics·Luigino CalzettaMaria Gabriella Matera
Feb 13, 2014·Basic & Clinical Pharmacology & Toxicology·Katharine H Abbott-Banner, Clive P Page
Mar 1, 1993·The European Respiratory Journal·P H QuanjerJ C Yernault
Aug 28, 2014·Expert Review of Respiratory Medicine·Daniel LangerDenis E O'Donnell
May 14, 2016·British Journal of Pharmacology·R Venkatasamy, D Spina

❮ Previous
Next ❯

Citations

Mar 7, 2020·The Korean Journal of Internal Medicine·Chin Kook Rhee, Deog Kyeom Kim
Dec 25, 2019·European Respiratory Review : an Official Journal of the European Respiratory Society·Mario CazzolaMaria Gabriella Matera
Dec 19, 2019·Pharmacological Reviews·M G MateraM Cazzola
May 22, 2020·Frontiers in Pharmacology·Marta JoskovaSona Franova
Apr 1, 2020·Frontiers in Pharmacology·Jonathan E Phillips
May 14, 2020·Journal of Personalized Medicine·Sean D McCarthyBrendan D Higgins
Jan 27, 2019·Expert Opinion on Investigational Drugs·Polyxeni NtontsiGeorgios Hillas
Sep 3, 2019·Expert Opinion on Investigational Drugs·Mario CazzolaMaria Gabriella Matera
Nov 12, 2020·American Journal of Physiology. Lung Cellular and Molecular Physiology·Jennifer M K NguyenVenkataramana K Sidhaye
Dec 18, 2020·Current Opinion in Pharmacology·Maria Gabriella MateraClive Page
Apr 30, 2021·International Journal of Chronic Obstructive Pulmonary Disease·Gary T FergusonKathleen Rickard
Jun 11, 2021·ERJ Open Research·Chris KyriakopoulosKonstantinos Kostikas
Aug 26, 2021·International Journal of Chronic Obstructive Pulmonary Disease·Clémence MartinNicolas Roche

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02542254
NCT03028142

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.